Whatever REDUCE-IT ultimately reveals (results from the completed study are expected in Q2 or Q3 2018), Salyer maintains Amarin has “a great story to tell, with or without the data.”
Five things for pharma marketers to know: Thursday, November 30, 2017
FDA plans new guidance to bring complex generics to market more quickly; BioMarin sells priority review voucher for $125 million; Takeda expects Zika clinical trial results next year
The FDA approves EpiPen competitor Auvi-Q for small children; pharma executives are warm up to Amazon; Purdue approached states about opioid-epidemic settlement
Five things for pharma marketers to know: Friday, November 17, 2017
AstraZeneca sales fall on generic competition; Anthem broadens access for Duchenne muscular dystrophy drug; researchers are developing new biopsy techniques